Exenatide Acetate

Details:

Exenatide acetate Chemical Properties
Melting point     >209°C (dec.)
storage temp.     Refrigerator, under inert atmosphere
solubility     Acetonitrile (Slightly), Water (Slightly)
form     Solid
color     White to Off-White
Sequence    H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
CAS DataBase Reference    141732-76-5(CAS DataBase Reference)
Safety Information
MSDS Information
Exenatide acetate Usage And Synthesis
Chemical Properties    Exenatide acetate is White Solid
Uses    A 39-amino acid peptide originally isolated from the salivary glands of the Gila monster (Heloderma suspectum), differs from exendin-3 only in two positions close to the N-terminus. Application of exenatide causes an increase in acinar cAMP without stimulating amylase release. As an incretin mimetic, exenatide acts as agonist of the glucagon-like peptide-1 (GLP-1) receptor. As GLP-1, though with prolonged activity, exenatide augments the postprandial production of insulin and suppresses secretion of glucagon. For this reason, exenatide has found use as a medication of diabetes II.
Uses    Application of exenatide acetate causes an increase in acinar cAMP without stimulating amylase release. As an incretin mimetic, exenatide acetate acts as agonist of the glucagon-like peptide-1 (GLP-1) receptor. As GLP-1, though with prolonged activity, exenatide acetate augments the postprandial production of insulin and suppresses secretion of glucagon. For this reason, exenatide acetate has found use as a medication of diabetes II.
Clinical Use    39-peptide known as an incretin mimetic; an agonist of glucagon-like peptide-1, used adjunctively in type II diabetes mellitus.
Drug interactions    Potentially hazardous interactions with other drugs
Anticoagulants: possibly enhances anticoagulant effect of warfarin.
Other nephrotoxins: avoid concomitant use.
Metabolism    Exenatide is eliminated through the kidneys by glomerular filtration followed by proteolytic degradation.